STANDARDS CASE 2-INTERIM REPORTING Caplan Pharma, Inc., Recently was sued by a c...

STANDARDS CASE 2-INTERIM REPORTING

Caplan Pharma, Inc., Recently was sued by a competitor for possible infringement of the competitor's patent on a top-selling flu vaccine. The plaintiff is suing for damages of 315 million. Caplan's CFO has discussed the case with legal counsel, who believes it is possible that Caplan will not be able to successfully defend the lawsuit. The CFO knows that current U.S. accounting guidelines require that contingencies (such as lawsuits) must be disclosed in the annual report when a loss is possible. However, she is unsure whether this rule must be applied in the preparation of interim financial statements. She also knows that disclosure is necessary only if the amount is material, but she is unsure whether materiality should be assessed in relation to results for the interim period or for the entire year.

Required

Search current U.S. accounting standards to determine whether contingencies are required to be disclosed in interim reports, and, if so. How materiality is to be determined. Identify the source of guidance for answering these questions.